An outbreak of acute hepatitis C among recipients of intravenous immunoglobulin

Kenneth Flora, Mark Schiele, Kent Benner, Anthony Montanaro, Wendy Johnston, Ruth Whitham, Richard Press

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: An association between therapy with intravenous immunoglobulin (IVIG, Gammagard, Baxter Healthcare Corp) and acute hepatitis C (HCV) was reported by the manufacturer in 1994. Objective: We sought to describe those patients at risk at our institution who developed HCV infection after IVIG (Gammagard) treatment(s). Materials: An inception cohort study of patients with exposure to contaminated IVIG in a university tertiary care institution. Twenty-three patients received suspect IVIG and presented to be screened for HCV via ELISA II and polymerase chain reaction techniques. We describe the demographics and clinical characteristics of patients diagnosed with hepatitis C infection from IVIG. Results: Ten of 23 (44%) patients who had received immunoglobulin (2 g/kg) for neurologic or immunologic disorders and were tested for anti-HCV were positive. All were also HCV-RNA positive by polymerase chain reaction. None had other HCV risk factors; all but two had normal aminotransferases documented prior to therapy. The patients had received monthly therapy for periods ranging from 2 to 60 months. Four patients were asymptomatic and the others had mild symptoms. One patient spontaneously became PCR negative within 12 months after exposure. Conclusion: Patients who received intravenous immunoglobulin (Gammagard, Baxter Healthcare Corp) between March, 1993, and February, 1994, are at risk for acute hepatitis C. The initial sequellae appear to be mild and spontaneous remission is possible.

Original languageEnglish (US)
Pages (from-to)160-162
Number of pages3
JournalAnnals of Allergy, Asthma and Immunology
Volume76
Issue number2
StatePublished - Feb 1996

Fingerprint

Intravenous Immunoglobulins
Hepatitis C
Disease Outbreaks
Polymerase Chain Reaction
Delivery of Health Care
Spontaneous Remission
Tertiary Healthcare
DNA-Directed RNA Polymerases
Therapeutics
Transaminases
Infection
Nervous System
Immunoglobulins
Cohort Studies
Enzyme-Linked Immunosorbent Assay
Demography

ASJC Scopus subject areas

  • Immunology and Allergy

Cite this

An outbreak of acute hepatitis C among recipients of intravenous immunoglobulin. / Flora, Kenneth; Schiele, Mark; Benner, Kent; Montanaro, Anthony; Johnston, Wendy; Whitham, Ruth; Press, Richard.

In: Annals of Allergy, Asthma and Immunology, Vol. 76, No. 2, 02.1996, p. 160-162.

Research output: Contribution to journalArticle

@article{34af95ef8c0d43b9b3acb26e5b5f9628,
title = "An outbreak of acute hepatitis C among recipients of intravenous immunoglobulin",
abstract = "Background: An association between therapy with intravenous immunoglobulin (IVIG, Gammagard, Baxter Healthcare Corp) and acute hepatitis C (HCV) was reported by the manufacturer in 1994. Objective: We sought to describe those patients at risk at our institution who developed HCV infection after IVIG (Gammagard) treatment(s). Materials: An inception cohort study of patients with exposure to contaminated IVIG in a university tertiary care institution. Twenty-three patients received suspect IVIG and presented to be screened for HCV via ELISA II and polymerase chain reaction techniques. We describe the demographics and clinical characteristics of patients diagnosed with hepatitis C infection from IVIG. Results: Ten of 23 (44{\%}) patients who had received immunoglobulin (2 g/kg) for neurologic or immunologic disorders and were tested for anti-HCV were positive. All were also HCV-RNA positive by polymerase chain reaction. None had other HCV risk factors; all but two had normal aminotransferases documented prior to therapy. The patients had received monthly therapy for periods ranging from 2 to 60 months. Four patients were asymptomatic and the others had mild symptoms. One patient spontaneously became PCR negative within 12 months after exposure. Conclusion: Patients who received intravenous immunoglobulin (Gammagard, Baxter Healthcare Corp) between March, 1993, and February, 1994, are at risk for acute hepatitis C. The initial sequellae appear to be mild and spontaneous remission is possible.",
author = "Kenneth Flora and Mark Schiele and Kent Benner and Anthony Montanaro and Wendy Johnston and Ruth Whitham and Richard Press",
year = "1996",
month = "2",
language = "English (US)",
volume = "76",
pages = "160--162",
journal = "Annals of Allergy, Asthma and Immunology",
issn = "1081-1206",
publisher = "American College of Allergy, Asthma and Immunology",
number = "2",

}

TY - JOUR

T1 - An outbreak of acute hepatitis C among recipients of intravenous immunoglobulin

AU - Flora, Kenneth

AU - Schiele, Mark

AU - Benner, Kent

AU - Montanaro, Anthony

AU - Johnston, Wendy

AU - Whitham, Ruth

AU - Press, Richard

PY - 1996/2

Y1 - 1996/2

N2 - Background: An association between therapy with intravenous immunoglobulin (IVIG, Gammagard, Baxter Healthcare Corp) and acute hepatitis C (HCV) was reported by the manufacturer in 1994. Objective: We sought to describe those patients at risk at our institution who developed HCV infection after IVIG (Gammagard) treatment(s). Materials: An inception cohort study of patients with exposure to contaminated IVIG in a university tertiary care institution. Twenty-three patients received suspect IVIG and presented to be screened for HCV via ELISA II and polymerase chain reaction techniques. We describe the demographics and clinical characteristics of patients diagnosed with hepatitis C infection from IVIG. Results: Ten of 23 (44%) patients who had received immunoglobulin (2 g/kg) for neurologic or immunologic disorders and were tested for anti-HCV were positive. All were also HCV-RNA positive by polymerase chain reaction. None had other HCV risk factors; all but two had normal aminotransferases documented prior to therapy. The patients had received monthly therapy for periods ranging from 2 to 60 months. Four patients were asymptomatic and the others had mild symptoms. One patient spontaneously became PCR negative within 12 months after exposure. Conclusion: Patients who received intravenous immunoglobulin (Gammagard, Baxter Healthcare Corp) between March, 1993, and February, 1994, are at risk for acute hepatitis C. The initial sequellae appear to be mild and spontaneous remission is possible.

AB - Background: An association between therapy with intravenous immunoglobulin (IVIG, Gammagard, Baxter Healthcare Corp) and acute hepatitis C (HCV) was reported by the manufacturer in 1994. Objective: We sought to describe those patients at risk at our institution who developed HCV infection after IVIG (Gammagard) treatment(s). Materials: An inception cohort study of patients with exposure to contaminated IVIG in a university tertiary care institution. Twenty-three patients received suspect IVIG and presented to be screened for HCV via ELISA II and polymerase chain reaction techniques. We describe the demographics and clinical characteristics of patients diagnosed with hepatitis C infection from IVIG. Results: Ten of 23 (44%) patients who had received immunoglobulin (2 g/kg) for neurologic or immunologic disorders and were tested for anti-HCV were positive. All were also HCV-RNA positive by polymerase chain reaction. None had other HCV risk factors; all but two had normal aminotransferases documented prior to therapy. The patients had received monthly therapy for periods ranging from 2 to 60 months. Four patients were asymptomatic and the others had mild symptoms. One patient spontaneously became PCR negative within 12 months after exposure. Conclusion: Patients who received intravenous immunoglobulin (Gammagard, Baxter Healthcare Corp) between March, 1993, and February, 1994, are at risk for acute hepatitis C. The initial sequellae appear to be mild and spontaneous remission is possible.

UR - http://www.scopus.com/inward/record.url?scp=0030020909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030020909&partnerID=8YFLogxK

M3 - Article

C2 - 8595535

AN - SCOPUS:0030020909

VL - 76

SP - 160

EP - 162

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

SN - 1081-1206

IS - 2

ER -